rasagiline + pramipexole

**Rasagiline + pramipexole** is an investigational, once-daily fixed-dose oral combination developed initially by Pharma Two B as P2B001 for **early Parkinson's disease**. It combines low-dose extended-release pramipexole, a dopamine receptor agonist, with extended-release rasagiline, a selective irreversible monoamine oxidase B inhibitor. The complementary mechanisms are intended to improve dopaminergic signaling while permitting lower pramipexole exposure and potentially reducing dopamine-agonist-associated adverse effects such as daytime somnolence. The P2B001 formulation contains pramipexole 0.6 mg and rasagiline 0.75 mg in extended-release capsules and completed Phase 3 evaluation in early Parkinson's disease.

Brand names

P2B001P-2B001P 2B001

Other names

pramipexole + rasagiline